Factors Determining Utilization of Stem Cell Transplant for Initial Therapy of Multiple Myeloma by Patient Race: Exploring Intra-racial Healthcare Disparities.
Sikander Ailawadhi(Jacksonville College), Asher Chanan‐Khan(WinnMed), Taimur Sher(Mayo Clinic in Florida), Ricardo Parrondo(Jacksonville College), Yaw Adu(Texas Tech University), Saurav Das(Griffin Hospital), David O. Hodge(WinnMed), Vivek Roy(Jacksonville College), Caitlyn Flott(Mayo Clinic in Florida), Jamie Elliott(Mayo Clinic in Florida), Andre Fernandez(Mayo Clinic in Florida), Ryan D. Frank(Mayo Clinic)
Cited by 0
Related Papers
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
|New England Journal of Medicine|2021|553
Ten-year postoperative results of penetrating keratoplasty
|Ophthalmology|1998|506
Early safety indicators of COVID-19 convalescent plasma in 5000 patients
|Journal of Clinical Investigation|2020|485